research Tofacitinib for the Treatment of Lichen Planopilaris: A Case Series
Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.
Search
for
Sort by
Research
210-240 / 1000+ results 
research Alopecia Areata and Tofacitinib: A Prospective Multicenter Study from a Saudi Population
Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
research Topical Tofacitinib for the Treatment of Alopecia Areata Affecting Facial Hair
Topical tofacitinib may effectively and safely regrow facial hair in some people with alopecia areata.
research Tofacitinib as a Pragmatic Treatment Choice for Alopecia Areata: A Retrospective Review
Tofacitinib was found to be a safe and effective treatment for hair regrowth in patients with alopecia areata.
research Alopecia – New Building Blocks
New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.
research Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
research Baricitinib Results in Eyebrow and Eyelash Growth in Patients With Alopecia Areata Who Do Not Achieve 20% or Less Scalp Hair Loss
Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.
research Annual Convention in the Time of COVID: The 2020 Dermatology Nurses' Association Meeting
The convention discussed various skin conditions and treatments, and highlighted the importance of vaccinations for patients on immune-altering medications.
research EE325 Budget Impact of Baricitinib for Patients with Severe Alopecia Areata
Adding Baricitinib for severe alopecia areata will have a small impact on a health plan's budget.
research JAMA Dermatology: The Year in Review, 2021
In 2021, JAMA Dermatology published significant findings on skin conditions post-COVID vaccination, melanoma surveillance, atopic dermatitis treatments, and confirmed that sun protection does not harm bone health.
research Baricitinib For Alopecia Areata
Baricitinib is effective in promoting hair growth in severe alopecia areata.
research Efficacy of Baricitinib in Patients With Various Degrees of Alopecia Areata Severity: Results From Brave-AA1 and Brave-AA2
Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.
research Unraveling the Secret Life of the Hair Follicle: From Fungi to Innovative Hair Loss Therapies
New hair loss treatments have evolved from understanding hair biology and patient needs.
research 22-Year-Old Male with Several Discrete Patches of Hair Loss
A 22-year-old man has alopecia areata, an autoimmune hair loss condition, with various treatments available.
research Medical Therapies
Combination therapies might work better for some vitiligo patients, but results vary.
research Personalized Medicine in the Field of Inflammatory Skin Disorders
Personalized medicine is important for treating skin disorders, with new treatments and connections to hormones and genetics being explored.
research Tumor Necrosis Factor Inhibitors and Janus Kinase Inhibitors in the Treatment of Cicatricial Alopecia: A Systematic Review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Janus Kinase Inhibitors in Dermatology: A Systematic Review
JAK inhibitors help with skin conditions but need more research on dosing and safety.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Various Applications of Tofacitinib and Ruxolitinib in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
research Janus Kinase Inhibitors Versus Other Biological Treatments in Alopecia Areata
Janus kinase inhibitors show promise in treating alopecia areata but need more safety research.
research Observational Real-World Evidence on the Efficacy and Safety of Janus Kinase Inhibitors in the Treatment of Moderate to Severe Active Ulcerative Colitis
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research Efficacy of Janus Kinase Inhibitors in Adult Patients With Alopecia Areata
Janus kinase inhibitors are effective and generally safe for treating hair loss in adults with alopecia areata.
research Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study
Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
research Treatment of Alopecia Areata With the Janus Kinase Inhibitor Upadacitinib: A Retrospective Cohort Study
Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.
research Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
JAK inhibitors show promise for treating various skin diseases.
research Janus Kinase Inhibitor as a Therapeutic Option in Alopecia Areata: Case Report
JAK inhibitors like tofacitinib can effectively treat severe alopecia areata.
research The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
JAK inhibitors show promise for treating hair loss in alopecia areata but need more clinical trials to confirm safety and effectiveness.
research Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib
Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
research The Relative Efficacy of Monotherapy With Janus Kinase Inhibitors, Dupilumab and Apremilast in Adults With Alopecia Areata: Network Meta-Analyses of Clinical Trials
JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.